difurfurylideneacetone profile

Cross-References

ID Source	ID
PubMed CID	1268245
CHEMBL ID	492863
SCHEMBL ID	979495
SCHEMBL ID	979497
MeSH ID	M0061289

Synonyms (36)

Synonym
HMS1474E05
difurfurylidene acetone
AKOS002347357
1,5-bis(2-furyl)-1,4-pentadien-3-one
difa
886-77-1
difurfurylideneacetone
1,4-pentadien-3-one, 1,5-bis(2-furanyl)-
1,5-di-2-furyl-1,4-pentadien-3-one
nsc 24065
1,5-difuryl-1,4-pentadien-3-one
1,5-di-2-furanyl-1,4-pentadien-3-one
1,4-pentadien-3-one, 1,5-di-2-furyl-
1,4-pentadien-3-one, 1,5-di-2-furanyl-
ai3-09311
einecs 212-955-2
1,5-di-2-furylpenta-1,4-dien-3-one
1,3-difurfurylideneacetone
3-pentadienone, 1,5-di-2-furyl-
NCGC00174777-01
CHEMBL492863
1,5-bis-(2-furanyl)-1,4-pentadien-3-one ,
A842838
(1e,4e)-1,5-bis(furan-2-yl)penta-1,4-dien-3-one
144850-49-7
(1e,4e)-1,5-di(furan-2-yl)penta-1,4-dien-3-one
26375-43-9
DTXSID3061265
SCHEMBL979495
SCHEMBL979497
SR-01000395043-1
sr-01000395043
XOOFLVNFEPIPIW-KQQUZDAGSA-N
ES-2009
1,5-di(furan-2-yl)penta-1,4-dien-3-one
A884719

Bioassays (11)

Assay ID	Title	Year	Journal	Article
AID1415618	Antifungal activity against fluconazole-resistant Candida krusei clinical isolate 2159 in presence of 8 ug/ml fluconazole by broth microdilution method	2017	MedChemComm, May-01, Volume: 8, Issue:5	Synthesis and synergistic antifungal effects of monoketone derivatives of curcumin against fluconazole-resistant
AID1415615	Antifungal activity against fluconazole-resistant Candida tropicalis clinical isolate 087 by broth microdilution method	2017	MedChemComm, May-01, Volume: 8, Issue:5	Synthesis and synergistic antifungal effects of monoketone derivatives of curcumin against fluconazole-resistant
AID1415613	Antifungal activity against fluconazole-resistant Candida krusei clinical isolate 2159 by broth microdilution method	2017	MedChemComm, May-01, Volume: 8, Issue:5	Synthesis and synergistic antifungal effects of monoketone derivatives of curcumin against fluconazole-resistant
AID1415614	Antifungal activity against fluconazole-resistant Candida albicans clinical isolate 103 by broth microdilution method	2017	MedChemComm, May-01, Volume: 8, Issue:5	Synthesis and synergistic antifungal effects of monoketone derivatives of curcumin against fluconazole-resistant
AID390731	Inhibition of Vaccinia virus DNA synthesis in by rapid plate assay	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Identification of non-nucleoside DNA synthesis inhibitors of vaccinia virus by high-throughput screening.
AID390732	Antiviral activity against Vaccinia virus WR in BSC1 cells assessed as reduction in plaque formation after 20 hrs	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Identification of non-nucleoside DNA synthesis inhibitors of vaccinia virus by high-throughput screening.
AID1415617	Antifungal activity against fluconazole-resistant Candida tropicalis clinical isolate 087 in presence of 8 ug/ml fluconazole by broth microdilution method	2017	MedChemComm, May-01, Volume: 8, Issue:5	Synthesis and synergistic antifungal effects of monoketone derivatives of curcumin against fluconazole-resistant
AID1415616	Antifungal activity against fluconazole-resistant Candida albicans clinical isolate 103 in presence of 8 ug/ml fluconazole by broth microdilution method	2017	MedChemComm, May-01, Volume: 8, Issue:5	Synthesis and synergistic antifungal effects of monoketone derivatives of curcumin against fluconazole-resistant
AID390734	Cytotoxicity against african green monkey BSC1 cells after 20 hrs WST-1 based assay	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Identification of non-nucleoside DNA synthesis inhibitors of vaccinia virus by high-throughput screening.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (16.67)	18.7374
1990's	1 (16.67)	18.2507
2000's	1 (16.67)	29.6817
2010's	3 (50.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	6 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
carbamates [no description available]	1.97	1	amino-acid anion
fluconazole Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.	2.15	1	conazole antifungal drug; difluorobenzene; tertiary alcohol; triazole antifungal drug	environmental contaminant; P450 inhibitor; xenobiotic
cidofovir anhydrous Cidofovir: An acyclic nucleoside phosphonate that acts as a competitive inhibitor of viral DNA polymerases. It is used in the treatment of RETINITIS caused by CYTOMEGALOVIRUS INFECTIONS and may also be useful for treating HERPESVIRUS INFECTIONS.. cidofovir anhydrous : Cytosine substituted at the 1 position by a 3-hydroxy-2-(phosphonomethoxy)propyl group (S configuration). A nucleoside analogue, it is an injectable antiviral used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients.	2.04	1	phosphonic acids; pyrimidone	anti-HIV agent; antineoplastic agent; antiviral drug; photosensitizing agent
tipindole tipindole: RN given refers to parent cpd; structure	2.04	1
5,5'-methylenedisalicylic acid 5,5'-methylenedisalicylic acid: inhibits attachment of ribosomes to microsomal membranes; RN given refers to parent cpd; structure in first source & Merck Index, 9th ed, #5934	2.04	1
quinoprazine quinoprazine: structure given in first source	2.04	1
stephenanthrine stephenanthrine: from the root of Stephania tetranda S. Moore & Dennettia tripetala; structure in first source. stephanthrine : An organic heterotetracyclic compound that is 2-(2H-phenanthro[3,4-d][1,3]dioxole in which the hydrogen at position 5 has been replaced by a 2-(dimethylamino)ethyl group.	2.04	1	cyclic acetal; organic heterotetracyclic compound; tertiary amino compound
(1E,4E)-1,5-bis(4-methoxyphenyl)penta-1,4-dien-3-one [no description available]	2.15	1	methoxybenzenes
curcumin Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.. curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa.	2.15	1	aromatic ether; beta-diketone; diarylheptanoid; enone; polyphenol	anti-inflammatory agent; antifungal agent; antineoplastic agent; biological pigment; contraceptive drug; dye; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; flavouring agent; food colouring; geroprotector; hepatoprotective agent; immunomodulator; iron chelator; ligand; lipoxygenase inhibitor; metabolite; neuroprotective agent; nutraceutical; radical scavenger
2-{[(9H-9-fluorenylmethoxy)carbonyl]amino}benzoic acid [no description available]	2.04	1	fluorenes

Condition	Indicated	Relationship Strength	Studies	Trials
Encephalitis, Polio [description not available]	0	2.06	1	0
Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)	0	2.06	1	0

difurfurylideneacetone

Cross-References

Synonyms (36)

Bioassays (11)

Research

Studies (6)

Study Types

difurfurylideneacetone

Cross-References

Synonyms (36)

Bioassays (11)

Research

Studies (6)

Study Types

Related Drugs (10)

Related Conditions (2)